NESS ZIONA, Israel--(BUSINESS WIRE)--Kamada (TASE:KMDA), a biopharmaceutical company engaged in the development, production and marketing of specialty life-saving biotherapeutics, announced today that it has entered into definitive agreements dated February 23, 2009 with Mr. Ralf Hahn, Chairman of the Board and one of the controlling shareholders, and UDT Med Holdings LLC, New York, to sell 2,621,723 shares of its common stock and 40% warrant coverage in a private allocation. The investors have agreed to purchase the shares at a purchase price of NIS 11.00 (~US$2.67) per share resulting in gross proceeds of US$7 million to Kamada.
